mirabelle

breast health, in your hands

We're building the first at-home breast screening device that helps women monitor their breast health between mammograms.

Be the first to know.

We're in pre-launch. Whether you're an investor, a future user, or just curious — we'd love to stay in touch.

Women are told to get a mammogram every 2 years. The remaining 23 months, they have no reliable way to check their breasts.

41 days

Is all it takes for the most aggressive breast cancer tumor to double in volume

23 months

The gap between mammograms on a biennial schedule

98.6%

5-year survival rate when caught at Stage 1. It drops to 26% by Stage 4.

Introducing mirabelle

Mirabelle is a medical device that transforms a subjective breast exam into a consistent, reproducible monthly screen — at home, between your mammograms.

Paired with an app, it helps women track changes over time and act when it matters.

We are pre-FDA clearance.

Traction

4 prototypes built $71K in grants won IPC international patent filed Validated by healthcare professionals at Yale, Harvard, Dartmouth & UCONN Clinical trial launching June 2026 in Ghana
Community

Join the Titty Committee

From our very first prototype, Mirabelle has been shaped by real feedback from our Titty Committee: women helping us build better breast health, one conversation at a time. Every feature, from the shape of the device to the softness of the material, has been co-created with them.

Your experience matters. Join to share your voice, test early ideas, and be part of a community that talks openly about breast health.

Make your voice heard

Tell us what matters to you and help shape how Mirabelle looks, feels and works.

Get early access

Be first to see prototypes, try new features and hear about our clinical progress.

Find your people

Join women who are breaking the silence around breast health and checking in on each other.

Sign up to join

What would you like to weigh in on? (optional)
Book a feedback chat ↗

Be the first to know.

We're in pre-launch. Whether you're an investor, a future user, or just curious — we'd love to stay in touch.